deeper look ge bioproduct rais fair
valu
visit lot trade show exhibitor last three week
dhr-buy acquisit ge life scienc appear compel
expect industri particip indic hold widest product portfolio
bioproduct industri combin custom list drive revenu
synergi margin expans announc acquisit ge life
scienc ls februari set guidanc core growth five year
earn accret lead industri consult bio-process technolog
consult estim bio-product capac increas
chromatographi technolog along upstream compon cell cultur media/
bioreactor cell/gen therapi workflow lead us believ initi guidanc
conserv rais fv core growth profil
increas visibl exceed expand margin beyond expect
view ge ls conserv rise biotechnolog therapeut
drive overal market growth rate compar legaci small-
molecul market rate howev see bio-product vendor
pall suppli reactor cell cultur media
chromatographi media filtrat product exceed growth rate
pharma re-tool scale product biotechnolog therapeut
highlight growth monthli mab prescript tracker
mab develop compar approv cell gene
therapi develop compar approv commerci success
biolog robust develop pipelin lead us believ
still early-in multi-year growth cycl guid
organ growth ge life scienc view routin conservat
given underli market growth rate ge market lead downstream
chromatographi posit bio-process crucial product
biolog ultim drive growth rate similar peer hsd-ldd
typic acquisit one key competit
advantag abil acquir strong brand name asset
perform drive growth/margin expans implement
world class danah busi system db strategi db focus
lean manufactur inventori manag improv sale market
contact funnel win rate exampl would pall beckman
coulter beckman coulter case acceler core growth
flat/down lsd visibl msd growth line improv
gross margin bp transform pall
busi lsd high-teen opm msd/hsd opm
best perform busi unit hand less
low-hang fruit captur ge life scienc give core growth
opm ultim believ world class db abl
drive margin expans medium/long term core growth
acceler captur market share end-to-end bioproduct
model updat updat model reflect deal
announc chang spin dental ipo assum
growth ge believ manag guidanc
conserv given ge strength downstream bio-product
underli growth market assum mn increment interest
expens bn increment debt interest rate fund deal
rais ep inclus
dental prior estim addit ge ls assum
free cash flow allow pay bn debt next
year exclud fund rais ipo dental
tee earn tee earn period
thursday april street look organ growth
visibl report organ upbeat commentari
manag head street look earn per
share janney
fair valu rais fair valu reiter buy
fv reach appli multipl ebitda estim
deduct estim debt per share guid
earn accret first year ownership life
scienc group typic valu around ev/ebitda expect
bp annual margin expans faster organ growth drive
million except per share data
dental revenu assum growth quarter spin occur quarter management guid
revenu growth rate refelect spin dental biz
impact foreign currenc
total sale
earn jv
management guid cent fx/tariff headwind
annual revenu break-out margin
total sale
revenu
